Network-Oriented Approaches to Anticancer Drug Response.

A long-standing paradigm in drug discovery has been the concept of designing maximally selective drugs to act on individual targets considered to underlie a disease of interest. Nonetheless, although some drugs have proven to be successful, many more potential drugs identified by the "one gene, one drug, one disease" approach have been found to be less effective than expected or to cause notable side effects. Advances in systems biology and high-throughput in-depth genomic profiling technologies along with an analysis of the successful and failed drugs uncovered that the prominent factor to determine drug sensitivity is the intrinsic robustness of the response of biological systems in the face of perturbations. The complexity of the molecular and cellular bases of systems responses to drug interventions has fostered an increased interest in systems-oriented approaches to drug discovery. Consonant with this knowledge of the multifactorial mechanistic basis of drug sensitivity and resistance is the application of network-based approaches for the identification of molecular (multi-)feature signatures associated with desired (multi-)drug phenotypic profiles. This chapter illustrates the principal network analysis and inference techniques which have found application in systems-oriented drug design and considers their benefits and drawbacks in relation to the nature of the data produced by network pharmacology.

[1]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[2]  Peter K. Sorger,et al.  Logic-Based Models for the Analysis of Cell Signaling Networks† , 2010, Biochemistry.

[3]  Liana Adam,et al.  Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. , 2005, Cancer research.

[4]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[5]  Julio Saez-Rodriguez,et al.  Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling , 2007, PLoS Comput. Biol..

[6]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[7]  N. Schork,et al.  Utility of network integrity methods in therapeutic target identification , 2013, Front. Genet..

[8]  K. Sachs,et al.  Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data , 2005, Science.

[9]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[10]  Wei Jiang,et al.  The analysis of the drug–targets based on the topological properties in the human protein–protein interaction network , 2009, Journal of drug targeting.

[11]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[12]  D. Pe’er,et al.  Principles and Strategies for Developing Network Models in Cancer , 2011, Cell.

[13]  Ernesto Estrada,et al.  Resistance Distance, Information Centrality, Node Vulnerability and Vibrations in Complex Networks , 2010, Network Science.

[14]  Yang Liu,et al.  Parameter estimation of dynamic biological network models using integrated fluxes , 2014, BMC Systems Biology.

[15]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[16]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[17]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[18]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[19]  Hiroaki Kitano,et al.  Violations of robustness trade-offs , 2010, Molecular systems biology.

[20]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[21]  Emmanuel Barillot,et al.  Combinatorial code governing cellular responses to complex stimuli , 2015, Nature Communications.

[22]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[23]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[24]  Albert-László Barabási,et al.  Erratum: Universality in network dynamics , 2013 .

[25]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[26]  Lei Yang,et al.  Characterization of essential genes by topological properties in the perturbation sensitivity network. , 2014, Biochemical and biophysical research communications.

[27]  Dianne P. O'Leary,et al.  Why Do Hubs in the Yeast Protein Interaction Network Tend To Be Essential: Reexamining the Connection between the Network Topology and Essentiality , 2008, PLoS Comput. Biol..

[28]  Ronald L. Rivest,et al.  Introduction to Algorithms , 1990 .

[29]  S. Strogatz.  Exploring complex networks , 2001, Nature.

[30]  Alison Stopeck,et al.  HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.

[31]  T. Vicsek,et al.  Uncovering the overlapping community structure of complex networks in nature and society , 2005, Nature.

[32]  Jean-Marc Schwartz,et al.  A global view of drug-therapy interactions , 2007, BMC pharmacology.

[33]  Zhi-Li Zhang,et al.  Geometry of Complex Networks and Topological Centrality , 2011, ArXiv.

[34]  Qi Wang,et al.  Extracting the Globally and Locally Adaptive Backbone of Complex Networks , 2014, PloS one.

[35]  Albert-László Barabási,et al.  Universality in network dynamics , 2013, Nature Physics.

[36]  A. Barabasi,et al.  Global organization of metabolic fluxes in the bacterium Escherichia coli , 2004, Nature.

[37]  Igor Goryanin,et al.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.

[38]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[39]  María Rodríguez Martínez,et al.  Elucidating Compound Mechanism of Action by Network Perturbation Analysis Graphical , 2015 .

[40]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[41]  Holger Fröhlich,et al.  Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance , 2009, BMC Systems Biology.

[42]  I. Chou,et al.  Recent developments in parameter estimation and structure identification of biochemical and genomic systems. , 2009, Mathematical biosciences.

[43]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[44]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[45]  B. Kholodenko,et al.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.

[46]  P. Csermely.  Strong links are important, but weak links stabilize them. , 2004, Trends in biochemical sciences.

[47]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[48]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[49]  David G. Covell,et al.  Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia , 2015, PloS one.

[50]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[51]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[52]  Ranadip Pal,et al.  A Kinase Inhibition Map Approach for Tumor Sensitivity Prediction and Combination Therapy Design for Targeted Drugs , 2011, Pacific Symposium on Biocomputing.

[53]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[54]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[55]  Haiyuan Yu,et al.  Target Essentiality and Centrality Characterize Drug Side Effects , 2013, PLoS Comput. Biol..

[56]  U. Alon.  Network motifs: theory and experimental approaches , 2007, Nature Reviews Genetics.

[57]  Li Wang,et al.  High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) , 2009, Cancer biology & therapy.

[58]  Ernesto Estrada,et al.  A vibrational approach to node centrality and vulnerability in complex networks , 2009, 0912.4307.

[59]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[60]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[61]  Stefan Wuchty,et al.  Essentiality and centrality in protein interaction networks revisited , 2015, BMC Bioinformatics.

[62]  Ernesto Estrada,et al.  The Structure of Complex Networks: Theory and Applications , 2011 .

[63]  W-C Hwang,et al.  Identification of Information Flow‐Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery , 2008, Clinical pharmacology and therapeutics.